Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 9 | 2023 | 489 | 3.840 |
Why?
|
| Antihypertensive Agents | 7 | 2023 | 170 | 2.430 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 613 | 2.150 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 164 | 2.050 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2019 | 40 | 1.780 |
Why?
|
| Diabetes Complications | 3 | 2021 | 120 | 1.770 |
Why?
|
| Medication Adherence | 6 | 2020 | 255 | 1.740 |
Why?
|
| Atherosclerosis | 3 | 2023 | 51 | 1.630 |
Why?
|
| Stroke | 6 | 2023 | 306 | 1.550 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 178 | 1.520 |
Why?
|
| Diabetes Mellitus | 4 | 2018 | 526 | 1.360 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 94 | 1.340 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2023 | 552 | 1.300 |
Why?
|
| Humans | 34 | 2023 | 18058 | 1.250 |
Why?
|
| Warfarin | 3 | 2021 | 74 | 1.250 |
Why?
|
| Retrospective Studies | 16 | 2021 | 2498 | 1.200 |
Why?
|
| Aged | 20 | 2023 | 6258 | 1.160 |
Why?
|
| Adult | 18 | 2023 | 7696 | 1.050 |
Why?
|
| Hypoglycemic Agents | 4 | 2016 | 289 | 1.040 |
Why?
|
| Aspirin | 2 | 2015 | 67 | 1.010 |
Why?
|
| Middle Aged | 21 | 2023 | 8073 | 1.000 |
Why?
|
| Anticoagulants | 3 | 2023 | 122 | 0.950 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 54 | 0.920 |
Why?
|
| Embolism | 1 | 2023 | 6 | 0.910 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 8 | 0.900 |
Why?
|
| Hyperkalemia | 1 | 2023 | 21 | 0.890 |
Why?
|
| Male | 22 | 2023 | 10173 | 0.890 |
Why?
|
| Female | 21 | 2023 | 12838 | 0.840 |
Why?
|
| Comorbidity | 8 | 2020 | 618 | 0.830 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 742 | 0.810 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 28 | 0.800 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 1956 | 0.790 |
Why?
|
| Prevalence | 7 | 2022 | 892 | 0.780 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 16 | 0.760 |
Why?
|
| Health Expenditures | 2 | 2019 | 81 | 0.760 |
Why?
|
| Diabetic Retinopathy | 2 | 2018 | 19 | 0.740 |
Why?
|
| Hemorrhage | 2 | 2023 | 63 | 0.740 |
Why?
|
| Health Care Costs | 2 | 2020 | 253 | 0.740 |
Why?
|
| Young Adult | 8 | 2023 | 2479 | 0.720 |
Why?
|
| Cholesterol, LDL | 2 | 2016 | 124 | 0.670 |
Why?
|
| Antiviral Agents | 1 | 2019 | 96 | 0.660 |
Why?
|
| Hepatitis C | 1 | 2019 | 66 | 0.660 |
Why?
|
| Risk Factors | 9 | 2023 | 3394 | 0.650 |
Why?
|
| Cost of Illness | 1 | 2018 | 97 | 0.610 |
Why?
|
| Societies, Medical | 1 | 2018 | 71 | 0.610 |
Why?
|
| Guideline Adherence | 1 | 2018 | 160 | 0.570 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 57 | 0.560 |
Why?
|
| Treatment Outcome | 5 | 2023 | 1259 | 0.550 |
Why?
|
| Incidence | 4 | 2023 | 1297 | 0.530 |
Why?
|
| Blood Coagulation | 1 | 2015 | 2 | 0.530 |
Why?
|
| Adolescent | 7 | 2021 | 3714 | 0.530 |
Why?
|
| Quality of Life | 1 | 2019 | 509 | 0.520 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 24 | 0.520 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 44 | 0.520 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 118 | 0.500 |
Why?
|
| Natural Language Processing | 1 | 2015 | 53 | 0.500 |
Why?
|
| Mass Screening | 2 | 2018 | 678 | 0.480 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 177 | 0.480 |
Why?
|
| California | 6 | 2020 | 2327 | 0.480 |
Why?
|
| Managed Care Programs | 1 | 2016 | 356 | 0.470 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 228 | 0.470 |
Why?
|
| Quality of Health Care | 1 | 2016 | 346 | 0.470 |
Why?
|
| United States | 5 | 2022 | 4119 | 0.460 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 397 | 0.440 |
Why?
|
| Risk Assessment | 5 | 2023 | 1137 | 0.430 |
Why?
|
| Administration, Oral | 3 | 2023 | 81 | 0.410 |
Why?
|
| Electronic Health Records | 1 | 2015 | 734 | 0.350 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 251 | 0.340 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1346 | 0.340 |
Why?
|
| Blood Pressure | 3 | 2023 | 280 | 0.340 |
Why?
|
| International Normalized Ratio | 2 | 2017 | 22 | 0.280 |
Why?
|
| Osteoarthritis | 2 | 2016 | 23 | 0.280 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 595 | 0.250 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1164 | 0.250 |
Why?
|
| Logistic Models | 2 | 2019 | 953 | 0.240 |
Why?
|
| Rivaroxaban | 1 | 2023 | 7 | 0.230 |
Why?
|
| Pyridones | 1 | 2023 | 7 | 0.230 |
Why?
|
| Dabigatran | 1 | 2023 | 8 | 0.230 |
Why?
|
| Aldosterone | 1 | 2023 | 2 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 705 | 0.230 |
Why?
|
| Potassium | 1 | 2023 | 20 | 0.230 |
Why?
|
| Creatinine | 1 | 2023 | 67 | 0.230 |
Why?
|
| Time Factors | 2 | 2018 | 1114 | 0.220 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 18 | 0.220 |
Why?
|
| Diuretics | 1 | 2022 | 18 | 0.220 |
Why?
|
| Age Factors | 3 | 2020 | 945 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 264 | 0.210 |
Why?
|
| Spironolactone | 1 | 2021 | 9 | 0.200 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2021 | 12 | 0.200 |
Why?
|
| Angioedema | 1 | 2021 | 8 | 0.200 |
Why?
|
| Kidney Diseases | 1 | 2021 | 53 | 0.200 |
Why?
|
| Bioprosthesis | 1 | 2021 | 2 | 0.200 |
Why?
|
| Heart Valves | 1 | 2021 | 4 | 0.200 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 19 | 0.190 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.190 |
Why?
|
| Drug Combinations | 1 | 2020 | 43 | 0.190 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 21 | 0.190 |
Why?
|
| Coinfection | 1 | 2020 | 30 | 0.180 |
Why?
|
| Recurrence | 1 | 2020 | 186 | 0.180 |
Why?
|
| Physicians | 1 | 2021 | 143 | 0.180 |
Why?
|
| Social Class | 1 | 2020 | 125 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2017 | 26 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 394 | 0.170 |
Why?
|
| Sex Factors | 1 | 2020 | 634 | 0.160 |
Why?
|
| Brain Ischemia | 2 | 2008 | 37 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 445 | 0.160 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 559 | 0.160 |
Why?
|
| Canada | 1 | 2017 | 66 | 0.150 |
Why?
|
| Testosterone | 1 | 2017 | 22 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 36 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2020 | 277 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 318 | 0.150 |
Why?
|
| Ethnic Groups | 1 | 2020 | 504 | 0.150 |
Why?
|
| Hospitalization | 2 | 2020 | 813 | 0.140 |
Why?
|
| Heart Failure | 1 | 2021 | 391 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2019 | 462 | 0.140 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 16 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2020 | 2631 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 745 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1309 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1255 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 13 | 0.120 |
Why?
|
| Algorithms | 1 | 2015 | 235 | 0.120 |
Why?
|
| Causality | 1 | 2013 | 43 | 0.120 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 481 | 0.110 |
Why?
|
| Budgets | 1 | 2011 | 6 | 0.100 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2010 | 28 | 0.090 |
Why?
|
| Cost Sharing | 1 | 2010 | 40 | 0.090 |
Why?
|
| Leukoaraiosis | 1 | 2008 | 1 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 299 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 510 | 0.070 |
Why?
|
| Orthomyxoviridae | 1 | 2020 | 5 | 0.050 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 14 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2023 | 205 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 36 | 0.050 |
Why?
|
| Seasons | 1 | 2020 | 99 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 293 | 0.040 |
Why?
|
| Androgens | 1 | 2017 | 13 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2017 | 5 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 28 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 65 | 0.040 |
Why?
|
| Models, Economic | 1 | 2011 | 21 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 86 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 86 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 77 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 84 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 69 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 90 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 2 | 0.020 |
Why?
|
| Korea | 1 | 2008 | 9 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 9 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 6 | 0.020 |
Why?
|
| Brain | 1 | 2008 | 45 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 92 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 319 | 0.020 |
Why?
|
Concepts
(156)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(14)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->